GlassScriptPhysician profile
Nora A Davis
NPI 1013978964
$5,950.96
in general payments reported to CMS, 2019-2025
32 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $695 · 2022: $968 · 2023: $2,092 · 2024: $1,437 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.03 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.63 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $451.82 | 2022-2023 | Austedo |
| Abbott Laboratories | $374.26 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $318.94 | 2022-2025 | Zepbound |
| Neurocrine Biosciences, INC. | $256.02 | 2023 | Ingrezza |
| Glaxosmithkline, LLC. | $245.84 | 2023-2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $243.07 | 2024-2025 | Airsupra |
| Insmed, INC. | $242.59 | 2024-2025 | Arikayce |
| Eisai INC. | $239.28 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.84 | 2023-2024 | |
| Novo Nordisk INC | $226.05 | 2021-2023 | Wegovy |
| Merz North America, INC. | $221.67 | 2021-2023 | Xeomin |
| Amgen INC. | $219.31 | 2021-2024 | Tepezza |
| Corcept Therapeutics | $212.48 | 2024-2025 | Korlym |
| Nevro Corp. | $190.34 | 2023 | Senza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $186.03 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $158.40 | 2023 | Inspire |
| Boston Scientific Corporation | $150.47 | 2023 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $123.71 | 2024 | Opsumit, Uptravi |
| Melinta Therapeutics, LLC | $116.90 | 2023 | Kimyrsa |
| Biosense Webster, INC. | $107.50 | 2024 | Carto 3 |
| Silk Road Medical, INC. | $94.50 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Sanofi-Aventis U.S. LLC | $94.23 | 2023 | |
| Abiomed | $92.83 | 2025 | |
| Genentech USA, INC. | $82.97 | 2021 | |
| Janssen Pharmaceuticals, INC | $69.07 | 2022 | |
| Cardiovascular Systems INC. | $65.78 | 2023 | |
| Tandem Diabetes Care, INC. | $61.15 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $60.28 | 2021 | |
| Arcutis Biotherapeutics, INC. | $54.55 | 2023 | |
| Medtronic, INC. | $42.46 | 2023 | Arctic Front Advance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.